Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2023; 14(5): 549-559
Published online May 15, 2023. doi: 10.4239/wjd.v14.i5.549
Published online May 15, 2023. doi: 10.4239/wjd.v14.i5.549
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
I Dewa Nyoman Wibawa, I Ketut Mariadi, Gde Somayana, Cokorda Istri Yuliandari Krisnawardani Kumbara, Department of Internal Medicine, Gastroentero-hepatology Division, Udayana University, Faculty of Medicine, Denpasar 80233, Bali, Indonesia
Dwijo Anargha Sindhughosa, Internal Medicine Resident, Udayana University, Faculty of Medicine, Denpasar 80233, Bali, Indonesia
Author contributions: Wibawa IDN contributed to conception of design, literature acquisition, drafting and critical revision of the article for important intellectual content and manuscript supervision; Mariadi IK contributed to conception of design, data searching, literature analysis, drafting and critical revision of the article for important intellectual content; Somayana G contributed to literature analysis, critical revision of the article for important intellectual content; Krisnawardani Kumbara CIY contributed to analysis of the study, drafting and editing of the paper; Sindhughosa DA contributed to conception of design, analysis of the study, drafting and revision of the article for important intellectual content. All authors approved the final version of the article.
Conflict-of-interest statement: All authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: I Dewa Nyoman Wibawa, MD, PhD, Professor, Department of Internal Medicine, Gastroentero-hepatology Division, Udayana University, Faculty of Medicine, Jalan PB Sudirman Denpasar, Denpasar 80233, Bali, Indonesia. agusbobwibawa@yahoo.com
Received: December 3, 2022
Peer-review started: December 3, 2022
First decision: December 26, 2022
Revised: February 2, 2023
Accepted: April 11, 2023
Article in press: April 11, 2023
Published online: May 15, 2023
Processing time: 163 Days and 0.1 Hours
Peer-review started: December 3, 2022
First decision: December 26, 2022
Revised: February 2, 2023
Accepted: April 11, 2023
Article in press: April 11, 2023
Published online: May 15, 2023
Processing time: 163 Days and 0.1 Hours
Core Tip
Core Tip: Type 2 diabetes mellitus (T2DM) is correlated with various metabolic disorders, including fatty liver. The influence of T2DM on incretin hormones contributed to fatty liver development. Impairment in lipid and glucose metabolism, fat oxidation, oxidative stress, and other effects lead to liver fat deposition. Therefore, drugs targeting the incretin hormones may provide beneficial effects on patients.